ALTERATIONS IN PRIMARY MOTOR CORTEX NEUROTRANSMISSION AND GENE EXPRESSION IN HEMI-PARKINSONIAN RATS WITH DRUG-INDUCED DYSKINESIA

D. LINDENBACH, M. M. CONTI, C. Y. OSTOCK, K. B. DUPRE AND C. BISHOP *

Behavioral Neuroscience Program, Department of Psychology, Binghamton University – State University of New York, Binghamton, NY, USA

Abstract—Treatment of Parkinson’s disease (PD) with dopamine replacement relieves symptoms of poverty of movement, but often causes drug-induced dyskinesias. Accumulating clinical and pre-clinical evidence suggests that the primary motor cortex (M1) is involved in the pathological physiology of PD and that modulating cortical activity may be a therapeutic target in PD and dyskinesia. However, surprisingly little is known about how M1 neurotransmitter tone or gene expression is altered in PD, dyskinesia or associated animal models. The present study utilized the rat unilateral 6-hydroxydopamine (6-OHDA) model of PD/dyskinesia to characterize structural and functional changes taking place in M1 monoamine innervation and gene expression. 6-OHDA caused dopamine pathology in M1, although the lesion was less severe than in the striatum. Rats with 6-OHDA lesions showed a PD motor impairment and development of dyskinesia. At the same time, expression of genes specifically involved in glutamate and GABA signaling were observed in dyskinesia when given L-DOPA or the D1 receptor agonist, SKF81297. M1 expression of two immediate-early genes (c-Fos and ARC) was strongly enhanced by either L-DOPA or SKF81297. At the same time, expression of genes specifically involved in glutamate and GABA signaling were either modestly affected or unchanged by lesion and/or treatment. We conclude that M1 neurotransmission and signal transduction in the rat 6-OHDA model of PD/dyskinesia mirror features of human PD, supporting the utility of the model to study M1 dysfunction in PD and the elucidation of novel pathophysiological mechanisms and therapeutic targets. © 2015 IBRO. Published by Elsevier Ltd. All rights reserved.

Key words: Parkinson’s disease, dyskinesia, L-DOPA, D1 agonist, primary motor cortex, immediate-early gene.

INTRODUCTION

Parkinson’s disease (PD) is principally caused by the loss of dopamine (DA) cells in the substantia nigra, leading to poverty of movement (Dauer and Przedborski, 2003; Jankovic, 2008). Treatment with L-DOPA relieves PD symptoms, but long-term use typically causes L-DOPA-induced dyskinesias (LID) that are in part due to supersensitization of DA D1 receptors (Cenci et al., 2011; Fedyer et al., 2011). An alternative strategy to treating PD has involved the use of primary motor cortex (M1) transcranial magnetic stimulation, which has shown promise in two meta-analyses (Fregni et al., 2005; Elahi et al., 2009).

Even though conventional anti-PD therapies modulate M1 activity and the region can be directly targeted for symptomatic relief, relatively little is known about how M1 monoamine transmission and gene expression are altered in human PD patients or in associated animal models (Lindenbach and Bishop, 2013). In the lone post-mortem study of M1 catecholamine fibers in PD patients, axons staining positively for tyrosine hydroxylase (TH; predominantly DA neurons: Hokfelt et al., 1977; Miner et al., 2006) were reduced by 24–74% compared to controls, depending on the cortical layer (Gaspar et al., 1991). In the popular 6-hydroxydopamine (6-OHDA) rat model of PD, reductions in M1 TH-positive fibers have been reported using optical density (Halje et al., 2012) or qualitative histology (Debeir et al., 2005), but there have been no attempts to rigorously quantify the extent of fiber loss. Changes in M1 monoamine tissue concentrations have not been assessed in humans or rat models of PD. Studies in parkinsonian primates have sometimes reported reductions in M1 DA, norepinephrine (NE) and serotonin (5-HT) levels, while other studies have found M1 monoamines to be equal to controls despite severe subcortical monoamine pathology (Pifl et al., 1991; Engeln et al., 2015). It is unclear how these changes in monoamine innervation effect cellular physiology in M1, although, at least in the prefrontal cortex, DA receptors modulate both glutamate and GABA currents (Lewis and O’Donnell, 2000; Seamans et al., 2001a,b).

A similar pattern may be occurring in M1, as animal models of PD typically show abnormal firing patterns of M1 glutamatergic and GABAergic cells (Watts and Mandir,
The influence of DA depletion and exogenous DA replacement on local M1 gene expression is unclear, although a key role for M1 DA is to facilitate motor learning, likely through promoting plasticity in M1 (Floel et al., 2005; Pasquerneau and Turner, 2011; Brazhnik et al., 2012; Halje et al., 2012).

Under normal circumstances, motor learning in M1 is associated with DA-dependent induction of the immediate-early gene c-Fos: expression levels rise while learning a motor task and decline nearly to control levels with repeated performance of the task (Kleim et al., 1996; Hosp and Luft, 2013). Since LID is often viewed as a pathological form of motor learning that is coincident with striatal c-Fos induction, it is possible that M1 c-Fos is involved in abnormal motor learning during LID (Calabresi et al., 2000; 2015; Mura et al., 2002). While multiple laboratories have reported that M1 c-Fos is induced by L-DOPA during dyskinesia (Ostock et al., 2011; Halje et al., 2012), these studies have been performed only in animals with multiple exposures to L-DOPA and the contribution of D1 receptors to this effect is unclear. Whereas c-Fos is critical for affecting transcriptional activity, another immediate-early gene, activity-regulated cytoskeletal-associated protein (ARC), is important for promoting synaptic plasticity in part through AMPA receptor trafficking, and may identify unique aspects of cortical plasticity (Bramham et al., 2008; Korb and Finkbeiner, 2011; Perez-Cadahia et al., 2011). Indeed, ARC protein was recently shown to be preferentially enhanced by L-DOPA among rats that displayed significant LID as opposed to more stable L-DOPA responders (Bastide et al., 2014).

The goal of the present study was to characterize structural and functional changes occurring in M1 in a widely used rat model of PD/LID, in order to spur further research and highlight therapeutic approaches. First, 6-OHDA-induced changes in M1 TH-fiber innervation and monoamine tissue concentrations were quantified using immunohistochemistry and high performance liquid chromatography (HPLC). Next, real-time reverse-transcriptase polymerase chain reaction (PCR) was used to examine changes in M1 gene expression after DA lesion and treatment with L-DOPA or the D1 receptor agonist SKF81297 (SKF). Our hypothesis was that 6-OHDA would reduce DA and NE innervation of M1, while DA replacement would pathologically enhance expression of M1 immediate-early genes and other genes involved in glutamate signaling, coincident with the induction of dyskinetic behavior.

EXPERIMENTAL PROCEDURES

Animals

All experiments used male Sprague–Dawley rats (Taconic Farms, Hudson, NY, USA) that were 9–11 weeks old at the start of the experiment (N = 86). Rats were pair-housed in plastic cages and given free access to water and standard laboratory rat food. The colony room was maintained at 22–23 °C on a 12-h light/dark cycle, with experiments taking place during the light cycle. Throughout the study, animals were cared for in full accordance with the guidelines of the Institutional Animal Care and Use Committee of Binghampton University and the most-current (2011) National Institutes of Health “Guide for the Care and Use of Laboratory Animals”.

Drugs

All drugs were delivered at a volume of 1 ml/kg. Buprenorphine hydrochloride (Hospira Inc., Lake Forest, IL, USA) was dissolved in saline. (±)SKF hydrobromide (Sigma–Aldrich, St. Louis, MO, USA) was dissolved in saline with 20% dimethyl sulfoxide. 6-OHDA hydrobromide and l-DOPA methyl ester hydrochloride (Sigma–Aldrich) were dissolved in saline with 0.1% ascorbic acid. Multiple doses of l-DOPA were used, but the peripheral decarboxylase inhibitor benserazide hydrochloride (Sigma–Aldrich) was always co-administered at a constant dose of 15 mg/kg. Sodium pentobarbital (Fort Dodge Animal Health, Fort Dodge, IA, USA) was suspended in an alcohol/dH2O mixture by the manufacturer. Desipramine hydrochloride and quinpirole hydrochloride (Sigma–Aldrich) were dissolved in dH2O.

Lesion surgeries

All rats received unilateral lesions to the medial forebrain bundle (MFB). In different experiments, sham or active lesions were created by infusing vehicle (Veh) or 6-OHDA, respectively. For analgesic purposes, rats were given buprenorphine (0.03 mg/kg; i.p.) immediately prior to surgery and 24 h after surgery. Animals were anesthetized with isoflurane (2–3% for 30–45 min; Baxter Healthcare, Deerfield, IL, USA) mixed with oxygen (1 L/min). Since PD patients show significant NE pathology in M1 (Gaspar et al., 1991), NE neurons were not protected from pathology using the NE transport blocker desipramine. The exception to this is experiment 3B, where rats were treated with desipramine (25 mg/kg, ip) 30 min prior to 6-OHDA infusion, since these rats were used as part of a different study (see experiment 1 of Dupre et al., 2013). The following coordinates relative to the bregma were used to target the MFB according to the rat brain atlas of Paxinos and Watson (1998): AP –1.8 mm; ML –2.0 mm; DV –8.6 mm, with the incisor bar 5 mm below the interaural line. A syringe with 26-gauge needle (Hamilton, Reno, NV, USA) was lowered into the target site and 6-OHDA (12 µg) or Veh was injected at a constant flow rate of 2 µl/min for 2 min. The needle was withdrawn 5 min later.

Forepaw adjusting steps (FAS) test

The FAS test is a measure of akinesia, a cardinal symptom of PD (Jankovic, 2008). Rats with > 80% unilateral striatal DA depletion take fewer steps with the lesioned side of the body (Chang et al., 1999). To perform the test, an experimenter blinded to treatment condition held the rat’s hindlimbs and one forelimb such that the free forelimb was forced to bear the rat’s body weight. Rats were moved laterally for 90 cm over 10 s while another experimenter

1992; Parr-Brownlie and Hyland, 2005; Pasquerneau and Turner, 2011; Brazhnik et al., 2012; Halje et al., 2012).
counted the number of steps taken. Each FAS test consisted of three trials for each forelimb in each direction (toward or away from a rat’s midline), for a total of 12 trials per rat. Total steps with the lesioned forelimb were divided by steps with the non-lesioned forelimb to derive a “percent intact” score: lower scores indicate greater motor impairment. FAS scores were the primary inclusion criteria for the present research: rats with a 6-OHDA lesion were only considered parkinsonian (and included in the data set) if they manifested <60% intact stepping.

Abnormal involuntary movements (AIMs) scale

The AIMs test is a metric of dyskinesia. Rats were monitored for AIMs using a procedure modified from Cenci and Lundblad (2007) and described in detail in Lindenbach et al. (2011). Rats were observed in clear-plastic cylinders and were rated by a trained observer (>95% reliability), every 10 min for 60–180 min (depending on the experiment). During each rating period, individual dyskinesia severity scores ranging from 0 (not present) to 4 (severe and not interruptible) were given for axial, limb and orolingual dyskinesias. The three AIMs subtypes were summed to create a single AIMs score for data analysis.

Statistical analysis

Statistical analysis was performed using SPSS (IBM, Chicago, IL, USA) with alpha set at 0.05. Since the AIMs scale has ordinal intervals, medians are used as the measure of central tendency. Such data were analyzed with the non-parametric Friedman test (within-subjects, omnibus), the Wilcoxon signed-rank test (within-subjects, contrasts), the Kruskal–Wallis test (between-subjects, omnibus) and the Mann–Whitney U (between-subjects, contrasts).

All other data were analyzed using standard ANOVAs and followed up by t-test contrasts if the relevant omnibus comparison was significant. Effect sizes for F tests are reported as partial eta squared ($\eta_p^2$), which measures the fraction of variance independently predicted by a single effect (range 0–1). If a given analysis was between-subjects and analyzed with parametric statistics, data more than 2.5 standard deviations from the group mean were considered outliers and discarded. This resulted in the removal of no data from exp 1, 1% of data from exp 2, 2% of data from exp 3A and 3% of data from exp 3B.

Experiment 1: Effect of lesion on striatal and M1 TH fiber innervation

Procedure. This experiment determined the effect of a MFB 6-OHDA lesion on striatal and M1 catecholamine innervation ($n = 12$; six per group; see Fig. 1 for diagram). Surgery was performed on rats as described above with animals receiving a unilateral MFB 6-OHDA lesion or Veh (sham) lesion. After 3 weeks of surgical recovery, rats were treated intermittently with multiple doses of l-DOPA (2–12 mg/kg) as well as the $D_1$ agonist SKF (0.08 and 0.8 mg/kg) and the $D_2$ agonist quinpirole (0.05 and 0.5 mg/kg; both injected s.c.). The AIMs scores from this portion of the experiment were used as unpublished pilot data. For subsequent immunohistochemical analyses, after a 10-d drug washout period, rats were transcardially perfused with 4% formaldehyde in phosphate-buffered saline.

Immunohistochemistry. Coronal sections (40 μm) were cut using a sliding microtome (Model SM2000R; Leica Microsystems, Bannockburn, IL, USA). Three sections each 1 mm apart were selected for processing (anterior to bregma, in mm: 2.6, 1.6, and 0.6). M1 was analyzed in all three slices and the striatum was examined in the two posterior sections. Prior to processing and between incubations, all slices were triple-washed with phosphate-buffered saline. Sections were first immersed in 0.3% H$_2$O$_2$ for 30 min. Subsequently, slices were placed in blocking buffer (phosphate-buffered saline with 1% bovine serum albumin, 1% normal goat serum and 0.4% Triton X-100 [Sigma–Aldrich]) for 120 min at room temperature. Sections were then incubated in a mouse anti-TH primary antibody (1:500 dilution in blocking buffer; Millipore, Billerica, MA, USA) at 4 °C overnight. Next, slices were bathed in a horse anti-mouse secondary antibody (1:200 dilution in blocking buffer; Vector Laboratories, Burlingame, CA, USA) at 4 °C for 120 min. Sections were then incubated for 1 h in a horse radish peroxidase-conjugated avidin–biotin mixture (VectaStain Elite ABC Kit, Vector Laboratories). For the chromagen step, SigmaFast kits (Sigma–Aldrich) containing 3,3′-diaminobenzidine and H$_2$O$_2$ were prepared according to the manufacturer’s instructions. After staining, slices were mounted on glass slides, dehydrated, defatted and cover slipped.

Quantification of TH immunoreactivity. Quantification of striatal TH staining was performed using optical density. Images of the striatum were captured with a photomicroscope at 2× magnification and analyzed with Image J software (NIH, Bethesda, MD, USA). Relative optical density was calibrated using the general utility Rodbard function fitted to an NIH step tablet. The primary somatosensory cortex (ipsilateral to each striata) was used as the reference for background staining, since this area receives very little DA innervation relative to the striatum (Pifl et al., 1991) and 6-OHDA did not affect optical density in this cortical region. Reported values are the optical density of the striatum minus the optical density of the primary somatosensory cortex.

In order to quantify M1 fiber density, a stereotaxic microscope (Axioscope 2 plus, Zeiss, Thornwood, NY, USA) was linked to a computer running the “Space Balls” feature of StereoInvestigator software (Version 10, MBF Bioscience, Williston, VT, USA). Space Balls achieves isotropy in three dimensions by superimposing a half-sphere into the tissue while an experimenter counts the number of times a fiber intersects the surface of the half-sphere. After outlining the M1 region,
the software selected ~20 sites in each M1 hemisphere of each of the three slices, for a total of ~120 sites per rat. Each site was visualized at 40× magnification and the number of fibers crossing a virtual hemisphere with 15-μm radius was quantified. Length estimates were derived from Mouton et al. (2002), with the computed length divided by the volume of tissue stereologically examined. Data are reported as nm of TH-positive fiber per μm³ of M1 tissue.

**Experiment 2: Effect of lesion and L-DOPA on M1 monoamine concentrations**

**Procedure.** This experiment determined how 6-OHDA lesion and L-DOPA administration alter monoamine concentrations in M1 (n = 28; seven per group; see Fig. 1 for diagram). Rats, as described above, received either a unilateral MFB 6-OHDA lesion or sham lesion. Three weeks after surgery, rats were given daily L-DOPA (12 mg/kg; s.c.) or Veh for 7 consecutive days. Rats were left untreated for days 8–14, during which time parkinsonian motor impairment was assessed with the FAS test. Daily L-DOPA (6 mg/kg) or Veh injections resumed on days 15–28, and rats were assessed for dyskinesia using the AIMs scale on day 27. On day 28, rats were rapidly decapitated 60 min after injection with L-DOPA (6 mg/kg) or Veh, a time point that corresponds with peak dyskinesia expression in lesioned animals given L-DOPA. M1 tissue was then processed for HPLC analysis of monoamine content.

**Monoamine tissue analysis.** HPLC coupled to electrochemical detection was performed on M1 tissue according to a protocol for monoamine analysis by Kilpatrick et al. (1986) and described in Dupre et al. (2011). Tissue was homogenized in ice-cold perchloric acid (0.1 M) with 1% ethanol and 0.02% EDTA. The homogenates were spun for 30 min at 14,000 g with the temperature maintained at 4°C. Aliquots of supernatant were analyzed for abundance of DA, the DA metabolite 3,4-dihydroxyphenylacetic acid (DOPAC), NE, 5-HT and the 5-HT metabolite 5-hydroxyindolacetic acid (5-HIAA). Samples were separated using a mobile phase composed of 90 mM NaH₂PO₄, 5.0 mM EDTA, 1.7 mM octane sulfonic acid and 10% acetonitrile, adjusted to pH 3.0 with r-phosphoric acid. The guard cell was set to +300 mV; the first electrode in the analytic cell was set to 0 mV and the second analytic electrode set to +250 mV. Standards of known concentrations were run across a range of 10⁻⁶ to 10⁻⁹ M and samples were plotted on the corresponding regression line. Values were adjusted to wet tissue weights and expressed as pg (of monoamine) per mg (of tissue).

**Experiment 3A: Effect of lesion and L-DOPA on mRNA expression in M1**

**Procedure.** This experiment determined how 6-OHDA lesions and L-DOPA alter the transcription of genes associated with cortical plasticity as well as glutamate and GABA signaling (n = 26; six to seven per group;
see Fig. 1 for diagram). Two weeks after surgery, rats with sham or 6-OHDA lesions were examined with the FAS test to verify parkinsonian motor impairment in 6-OHDA-lesioned animals and create equivalently parkinsonian treatment groups. One week later ("day 1"), rats were given daily injections of L-DOPA (6 mg/kg; s.c.) or Veh for 14 d. During this time, AIMs were monitored on days 1, 8 and 14 for 180 min. The FAS test was performed 60 min after drug injection on days 2 and 13. On day 15, rats in the "Acute L-DOPA" and "Chronic L-DOPA" groups received L-DOPA (6 mg/kg), while others received Veh. Subsequently, rats were monitored for AIMs for 60 min (six total ratings per rat); at 65 min post-injection, rats were decapitated for M1 mRNA analysis. M1 tissue was examined bilaterally for transcription levels of seven genes: 1. β-actin (as housekeeper); 2. c-Fos; 3. ARC; 4. the NMHD receptor subunit NR2A; 5. the NMDA receptor subunit NR2B; 6. vesicular glutamate transporter type 1 (VGLUT1); 7. glutamic acid decarboxylase 67 kDa (GAD67).

Real-time reverse-transcriptase PCR. Tissue was lysed with TRIzol (Life Technologies, Grand Island, NY, USA), mixed with phenol/chloroform and centrifuged at 12,000 g for 15 min. mRNA was precipitated with 70% ethanol and purified using RNaseasy columns (Qiagen, Valencia, CA, USA). Concentration of mRNA was determined via spectrophotometry using a Nanodrop (Thermo-Fischer Scientific, Waltham, MA, USA). cdNA was amplified with the IQ SYBR Green Supermix kit (BioRad, Hercules, CA, USA). A reaction master mix of volume 40 µl consisted of 20-µl SYBR Green, 17.6-µl RNase-free water, 0.4-µl cdNA template, and 2-µl of sample. From each master mix, 10 µl was pipetted in triplicate into a 384-well plate and analyzed using a CFX1000 Thermal Cycler (BioRad). Each gene was amplified for 40 cycles lasting 90 s each: 30 s at 95°C to denature cdNA, 30 s at 57–60°C (depending on primer sequence) to allow primers to bind and 30 s at 72°C to extend fragments. Relative gene expression was quantified using the 2-ΔΔCT method, with expression levels for transcripts of interest normalized to observed β-actin levels for each sample. Relative expression was then normalized to 100% of ultimate control values.

Primer sequences. Gene sequences were obtained from GenBank at the National Center for Biotechnology Information and primer specificity was verified by the Basic Local Alignment Search Tool (http://www.ncbi.nlm.nih.gov/). The primer sequences used (forward/reverse) were as follows: β-actin (5'-AGC ATC ACC CCA TTT GAT GT-3'/5'-GTC GTA CCA CTG GCA TTG TTG-3'); c-Fos (5'-CCA AGC GGA GAC AGA TCA AC-3'/5'-AAG TCC AGG GAG GTC ACA GA-3'); ARC (5'-TCA GAC CAT CAC AGA ACA CCT TT-3'/5'-CCC TGG GTT GTG CCT AC-3'); NR2A (5'-GCT ACA CAC CCT GCA CCA ATT-3'/5'-CAC CTG GTA TCC TTC AGT GA-3'); NR2B (5'-CCC AAC ATG ATC TCT TCT CCA TTA A-3'/5'-CAG CTA GTC GGC TCT CTT GGT T-3'); GAD67 (5'-CAC AAA CTC AGC GGC ATA GA-3'/5'-GAC CAG GAT GGC AGC ACA CT-3'); VGLUT1 (5'-GCC TTT TGC GTT TCC TAT GC-3'/5'-GGA GAT GCT GGG GTG TAG TG-3').

Experiment 3B: Effect of D1 activation on mRNA expression in M1

Procedure. All rats received a unilateral MFB 6-OHDA lesion (n = 20; six to seven per group; see Fig. 1 for diagram). Two weeks after surgery, the FAS test was used to assign rats to equivalently parkinsonian groups. One week later, on three sessions 2–3 d apart, one group of rats received Veh while two groups of rats received the D1 agonist SKF (0.8 mg/kg; s.c.). This treatment regimen has been shown to produce stable dyskinesia (Dupre et al., 2008, 2011). Immediately after injection, rats were monitored for AIMs for 120 min. Two days later, rats were given one final injection: two groups received Veh while one group received SKF (0.8 mg/kg). Rats were rated for AIMs for 120 min and decapitated for M1 mRNA analysis, using the same PCR technique described in ‘Real-time reverse-transcriptase PCR’ and ‘Primer sequences’ sections. Additional data from these rats have been previously reported in experiment 1 of Dupre et al. (2013). For the present experiment, only c-Fos and ARC (along with the housekeeper β-actin) were examined, given the modest modulation of other genes by L-DOPA treatment in experiment 3A.

RESULTS

Experiment 1: Effect of lesion on striatal and M1 TH fiber innervation

This experiment examined the effect of 6-OHDA lesion on TH fiber innervation in the striatum (using optical density) and in M1 (using stereology). The behavioral phenotype of Parkinsonism was verified with the FAS test; rats with a 6-OHDA lesion averaged 43% intact stepping and took significantly fewer steps with their affected forelimb than sham-lesioned rats (t10 = 8.86, p < .001). Effects on TH-positive fibers were determined with a 2×2 mixed-model ANOVA: Hemisphere (Ipsilateral or Contralateral [to Lesion]) × Lesion (6-OHDA or Sham).

Striatal TH. Omnibus ANOVA showed a main effect of hemisphere (F1,10 = 50.13, p < .001, ηp2 = .834) and 6-OHDA lesion reduced striatal optical density (F1,10 = 23.05, p = .001, ηp2 = .697). Importantly, there was a hemisphere × lesion interaction (F1,10 = 77.88, p < .001, ηp2 = .886). 6-OHDA-lesioned rats had a 99% reduction in ipsilateral striatal TH optical density compared to the contralateral striata (Fig. 2A, B; t5 = 12.65, p < .001).

M1 TH. The results of the 2×2 ANOVA showed there were fewer fibers in the ipsilateral hemisphere (F1,10 = 21.55, p = .001, ηp2 = .683), fewer fibers in 6-OHDA-lesioned animals (F1,10 = 9.48, p = .012, ηp2 = .487) and there was a hemisphere × lesion interaction (F1,10 = 18.85, p = .001, ηp2 = .653). Animals with 6-OHDA lesions averaged a 75% reduction
in the density of TH-positive fibers ipsilateral vs. contralateral to lesion (Fig. 2C–E; $t_{5} = 5.76$, $p = .002$).

**Experiment 2: Effect of lesion and L-DOPA on M1 monoamine concentrations**

As a complement to experiment 1, we next determined how 6-OHDA lesion and L-DOPA impacted monoamine tissue concentrations in M1. Rats in this experiment with a 6-OHDA lesion averaged 44% intact stepping and took fewer steps with their lesioned forelimb than sham-lesioned animals with the same forelimb ($t_{26} = 6.76$, $p < .001$). After chronic L-DOPA (6 mg/kg) exposure, 6-OHDA-lesioned animals that were given L-DOPA showed significant dyskinesia (as measured by the AIMS test) compared with 6-OHDA-lesioned animals treated with Veh ($Z = 3.13$, $p = .002$). Specifically within the ipsilateral hemisphere, when animals were given Veh, DA levels were the same between sham animals and those with a 6-OHDA lesion. Systemic L-DOPA increased DA among animals with a sham lesion ($t_{10} = 6.64$, $p < .001$) and among those with a 6-OHDA lesion ($t_{14} = 5.51$, $p < .001$). However, sham animals given L-DOPA displayed greater M1 DA content than 6-OHDA-lesioned animals given L-DOPA ($t_{12} = 3.05$, $p = .010$), suggesting greater synthesis of DA from L-DOPA in shams.

**DA.** Main effects of lesion and treatment showed that 6-OHDA reduced DA ($F_{1,24} = 9.80$, $p = .005$, $\eta_{p}^{2} = .290$), treatment with L-DOPA increased DA ($F_{1,24} = 168.40$, $p < .001$, $\eta_{p}^{2} = .875$) and there was a lesion * treatment interaction ($F_{1,24} = 5.33$, $p = .030$, $\eta_{p}^{2} = .182$).

**DOPAC.** Overall analysis revealed main effects of hemisphere ($F_{1,23} = 8.42$, $p = .008$, $\eta_{p}^{2} = .268$) and treatment ($F_{1,23} = 29.54$, $p < .001$, $\eta_{p}^{2} = .562$). Importantly, there was a hemisphere * lesion interaction ($F_{1,23} = 6.23$, $p = .023$, $\eta_{p}^{2} = .213$). In Veh-treated rats, DOPAC levels did not differ between 6-OHDA-lesioned animals and shams. L-DOPA increased DOPAC concentrations among sham animals ($t_{9} = 4.34$, $p = .002$) and 6-OHDA-lesioned animals ($t_{14} = 2.66$, $p = .019$).

**NE.** Omnibus ANOVA results showed a main effect of hemisphere ($F_{1,24} = 64.08$, $p < .001$, $\eta_{p}^{2} = .728$). An effect of lesion showed that 6-OHDA reduced NE ($F_{1,24} = 15.13$, $p = .001$, $\eta_{p}^{2} = .387$) with a further
reduction in NE by treatment with L-DOPA ($F_{1,24} = 7.64$, $p = .011, \eta^2_p = .242$). There was also a hemisphere * lesion interaction ($F_{1,24} = 40.37$, $p < .001, \eta^2_p = .627$). In Veh-treated animals, NE levels were lower among animals given 6-OHDA than among shams ($t_{12} = 2.49, p = .028$). Similarly, among animals given L-DOPA, 6-OHDA-lesioned animals had significantly less NE than sham animals ($t_{12} = 8.69, p < .001$).

5-HT and 5-HIAA. Analysis of 5-HT with a three-way ANOVA yielded no significant effects. Analyzing the 5-HT metabolite 5-HIAA, there was only a main effect of lesion showing that 6-OHDA lesion increased 5-HIAA ($F_{1,24} = 4.59, p = .042; \eta^2_p = .161$). No planned contrasts were conducted.

**Table 1. Effect of 6-OHDA and L-DOPA on M1 monoamines and their metabolites**

<table>
<thead>
<tr>
<th>Hemisphere</th>
<th>Lesion</th>
<th>Treatment</th>
<th>DA</th>
<th>DOPAC</th>
<th>NE</th>
<th>5-HT</th>
<th>5-HIAA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ipsilateral</td>
<td>Sham</td>
<td>Vehicle</td>
<td>33 ± 2</td>
<td>43 ± 3</td>
<td>279 ± 22</td>
<td>327 ± 11</td>
<td>3513 ± 234</td>
</tr>
<tr>
<td></td>
<td>Contralateral</td>
<td>–</td>
<td>35 ± 3</td>
<td>48 ± 4</td>
<td>305 ± 12</td>
<td>258 ± 13</td>
<td>3551 ± 199</td>
</tr>
<tr>
<td>Ipsilateral</td>
<td>6-OHDA</td>
<td>Vehicle</td>
<td>29 ± 5</td>
<td>32 ± 7</td>
<td>126 ± 50</td>
<td>291 ± 25</td>
<td>3679 ± 289</td>
</tr>
<tr>
<td></td>
<td>Contralateral</td>
<td>–</td>
<td>33 ± 2</td>
<td>52 ± 9</td>
<td>343 ± 13</td>
<td>346 ± 79</td>
<td>4212 ± 292</td>
</tr>
<tr>
<td>Ipsilateral</td>
<td>Sham</td>
<td>L-DOPA (6 mg/kg)</td>
<td>94 ± 9</td>
<td>85 ± 10</td>
<td>243 ± 14</td>
<td>239 ± 22</td>
<td>3187 ± 135</td>
</tr>
<tr>
<td></td>
<td>Contralateral</td>
<td>–</td>
<td>88 ± 4</td>
<td>83 ± 2</td>
<td>270 ± 5</td>
<td>240 ± 16</td>
<td>3484 ± 177</td>
</tr>
<tr>
<td>Ipsilateral</td>
<td>6-OHDA</td>
<td>L-DOPA (6 mg/kg)</td>
<td>66 ± 5</td>
<td>54 ± 5</td>
<td>36 ± 18</td>
<td>664 ± 305</td>
<td>3651 ± 146</td>
</tr>
<tr>
<td></td>
<td>Contralateral</td>
<td>–</td>
<td>76 ± 6</td>
<td>99 ± 16</td>
<td>284 ± 20</td>
<td>231 ± 20</td>
<td>3846 ± 242</td>
</tr>
</tbody>
</table>

Rats received unilateral injections of 6-hydroxydopamine (6-OHDA) or sham into the medial forebrain bundle ($n = 7$ per group). After recovery, rats were treated with daily L-DOPA 6 mg/kg or vehicle (Veh) and decapitated 60 min after final injection. Primary motor cortex tissue was processed via high performance liquid chromatography for concentrations of dopamine (DA), the DA metabolite 3,4-dihydroxyphenylacetic acid (DOPAC), norepinephrine (NE), serotonin (5-HT) or the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA). Reported values are mean pg (of monoamine) per mg (of tissue) ± SEM. Individual planned contrasts were only performed on the ipsilateral hemisphere.* $p < .05$ vs. Sham + Veh; $\# p < .05$ vs. 6-OHDA + Veh; $\$ p < .05$ vs. Sham + L-DOPA.

**Experiment 3A: Effect of lesion and L-DOPA on mRNA expression in M1**

This experiment examined how M1 gene expression is altered by 6-OHDA lesion and/or L-DOPA treatment. In this cohort, rats with a 6-OHDA lesion averaged 26% intact stepping and took fewer steps with their lesioned forelimb than sham rats with their sham-lesioned forelimb ($t_{24} = 21.32, p < .001$). Rats were then treated with daily L-DOPA (6 mg/kg) or Veh for 14 d and FAS was performed again on days 2 and 13 of treatment. Change in motor performance across days was analyzed with a 4 X 2 mixed-model ANOVA: Group (Sham – Veh, Lesion – Veh, Lesion – Acute L-DOPA, Lesion – Chronic L-DOPA) * Day (Baseline, Day 2, Day 13). Results revealed an effect of group ($F_{3,22} = 85.90, p < .001, \eta^2_p = .921$) and a group * day interaction ($F_{6,44} = 4.06, p = .003, \eta^2_p = .356$). Planned comparisons were conducted comparing day 2 and 13 to baseline for each group. As seen in Fig. 3A, rats receiving chronic L-DOPA showed a trend for increased stepping on day 2 ($t_{6} = 2.14, p = .076$) and a significant improvement in stepping on day 13 ($t_{6} = 3.77, p = .009$).

As seen in Fig. 3B, for rats given chronic L-DOPA, dyskinesia scores increased after repeated exposures to L-DOPA ($n = 7; \chi^2 = 8.00, p = .018$), with rats showing
more AIMs on day 8 ($Z = 2.20$, $p = .028$) and day 14 ($Z = 2.37$, $p = .018$) relative to day 1 of L-DOPA. After the final injection on day 15, AIMs were measured for 60 min (prior to tissue harvest); rats given chronic L-DOPA showed greater AIMs than rats given acute L-DOPA, although this was not statistically significant ($Z = 1.65$, $p = .100$), likely due to the limited sampling window relative to normal AIMs sessions (180 min).

Bilateral M1 tissue was collected on day 15, processed for real-time PCR and analyzed with a $2 \times 4$ mixed model ANOVA: Hemisphere (ipsilateral vs. Contralateral [to lesion or Sham]) $\times$ Group (Sham – Veh, Lesion – Veh, Lesion – Acute L-DOPA, Lesion – Chronic L-DOPA). ANOVA of housekeeper $\beta$-actin expression revealed no significant effects, demonstrating that levels were equivalent across groups.

c-Fos. The immediate-early gene c-Fos was examined as it is a general transcription factor and a marker of motor learning in M1 (Perez-Cadahia et al., 2011; Hosp and Luft, 2013; Fig. 4A). The $2 \times 4$ ANOVA revealed an effect of hemisphere ($F_{1,22} = 45.50$, $p < .001$, $\eta^2_p = .674$), a group effect ($F_{3,22} = 17.36$, $p < .001$, $\eta^2_p = .703$) and a hemisphere $\times$ group interaction ($F_{3,22} = 20.65$, $p < .001$, $\eta^2_p = .738$). We next performed between-subjects comparisons in the ipsilateral hemisphere. Lesion alone did not alter c-Fos expression ($t_{11} = 0.16$, $p = .879$). However, compared to lesion alone, c-Fos was induced ipsilaterally to lesion by both acute L-DOPA ($t_{10} = 5.41$, $p < .001$) and chronic L-DOPA ($t_{10} = 5.09$, $p < .001$). In the contralateral hemisphere, c-Fos expression was significantly increased after acute L-DOPA ($t_{10} = 2.81$, $p = .018$). To assess the hemisphere $\times$ group interaction further, we determined if L-DOPA was preferentially increasing M1 c-Fos in the ipsilateral hemisphere using a paired-samples $t$-test. Greater c-Fos mRNA was seen in the ipsilateral vs. contralateral M1 for rats given acute L-DOPA ($t_5 = 5.25$, $p = .003$) and for rats given chronic L-DOPA ($t_5 = 6.09$, $p = .001$).

Next, AIMs scores were correlated with percent change in c-Fos in both the ipsilateral and contralateral hemisphere among rats that received acute and chronic L-DOPA. We found a significant positive correlation between total AIMs and c-Fos mRNA ipsilateral to lesion in rats given acute L-DOPA ($r^2 = .820$, $p = .013$; Fig. 7A). Interestingly, expression of c-Fos was not significantly correlated with behavior contralateral to lesion or in rats given chronic L-DOPA (Fig. 7B–D).

ARC. Another immediate-early gene, ARC, was investigated, since it has been implicated in synaptic plasticity and receptor trafficking (Bramham et al., 2008). ANOVA results revealed an effect of group ($F_{3,22} = 5.63$, $p = .005$), but no other significant effects. As compared to sham, 6-OHDA lesion alone slightly increased ARC expression contralateral to lesion (to 143% of controls; $t_{11} = 2.58$, $p = .026$; Fig. 4B). Ipsilateral to lesion, ARC expression was more strongly increased by both acute L-DOPA (to 368% of controls; $t_{10} = 2.33$, $p = .042$) and chronic L-DOPA (to 373% of controls; $t_{11} = 2.81$, $p = .017$) as compared to Veh-treated animals. Changes in ARC expression were not significantly correlated with AIMs behavior.

**NMDA NR2A and NR2B.** The NMDA NR2A subunit, which promotes long-term potentiation, was examined given the role of DA in facilitating M1 plasticity (Fig. 5A; Liu et al., 2004; Hosp and Luft, 2013). Omnibus ANOVA revealed no main effects, but there was a hemisphere $\times$ group interaction ($F_{3,22} = 3.10$, $p = .048$, $\eta^2_p = .297$). Rats given acute L-DOPA showed less NR2A mRNA in their ipsilateral hemisphere compared to both their own contralateral hemisphere ($t_5 = 2.63$, $p = .047$) and the ipsilateral side of lesioned rats treated with Veh ($t_{10} = 2.77$, $p = .020$). The NR2B subunit, known to promote long-term depression, was also investigated (Liu et al., 2004), but no significant ANOVA effects were observed (Fig. 5B).

**VGLUT1.** VGLUT1 is a key glutamate transporter in cortical neurons and changes in striatal VGLUT1 protein are evident in the 6-OHDA rat model of PD (Massie et al., 2010; Villalba and Smith, 2011). There were no changes in mRNA levels of VGLUT1 in the present study (Fig. 5C).

**GAD67.** Finally, the activity of GAD67 was used to assay the activity state of cortical GABA interneurons (Lewis et al., 2005), but no significant effects were found (Fig. 5D).

**Fig. 4.** Effect of L-DOPA on mRNA transcription of the immediate-early genes c-Fos and ARC within the primary motor cortex (M1; $n = 6–7$ per group). Rats received a unilateral lesion with 6-hydroxydopamine (or sham). After recovery, rats were treated for 14 d with Vehicle (Veh), except rats in the “Chronic” condition, which received daily L-DOPA (6 mg/kg). The next day, rats in the “Acute” and “Chronic” groups received L-DOPA (6 mg/kg), while others received Veh. All rats were decapitated 65 min later and M1 tissue was analyzed via real-time polymerase chain reaction. Hemispheres are denoted as either ipsilateral or contralateral (to lesion or sham). Percent change in mRNA was normalized to control ("Sham – Veh [contralateral]"). (A) c-Fos mRNA. (B) ARC mRNA. * $p < .05$ vs. Lesion – Veh (ipsilateral); ** $p < .05$ vs. Lesion – Veh (contralateral); *** $p < .05$ vs. own contralateral hemisphere.
Experiment 3B: Effect of D<sub>1</sub> activation on mRNA expression in M1

One potential mechanism of LID is the supersensitization of D<sub>1</sub> receptors (Cenci et al., 2011; Feyder et al., 2011). Given the data from experiment 3A, suggesting that LID is associated with increases in M1 immediate-early gene expression, we chose to investigate these genes in animals treated with a D<sub>1</sub> receptor agonist at a dose that provokes dyskinesia (Dupre et al., 2011, 2013). Parkinsonian status was verified in these rats by showing that rats averaged 36% intact stepping on the FAS test, taking fewer steps with their lesioned forelimb than their intact forelimb ($t_{19} = 16.00$, $p < .001$). Animals were given three injections of the D<sub>1</sub> agonist SKF or Veh over a 7-d period and monitored for AIMs after each injection. Friedman test showed that AIMs increased with repeated exposure to SKF ($n = 14$; $\chi^2 = 21.42$, $p < .001$; Fig. 6A). Further analyses showed that AIMs increased on session 2 of SKF relative to session 1 ($Z = 3.30$, $p = .001$), but did not change on session 3 relative to session 2 ($Z = 0.49$, $p = .624$), suggesting animals were fully sensitized to SKF (Dupre et al., 2011, 2013).

Bilateral M1 tissue was collected on session 4, processed for real-time PCR and analyzed with a 2×3 mixed model ANOVA: Hemisphere (ipsilateral vs. contralateral) × Group (Lesion – Veh, Lesion – Veh (SKF primed), Lesion – Chronic SKF). Omnibus ANOVA for β-actin revealed a main effect of hemisphere ($F_{1,17} = 4.79$, $p = .043$, $\eta^2_p = .220$), whereby the ipsilateral hemisphere averaged 16% less β-actin mRNA than the contralateral side. Given the large effect sizes for target genes in this cohort (Fig. 6B, C) and considering that target gene expression was adjusted to housekeeper gene expression, the small difference in housekeeper expression should not alter data interpretation.

c-Fos. Upon analysis of expression of the immediate-early gene c-Fos, there was a main effect of hemisphere ($F_{1,17} = 18.10$, $p = .001$, $\eta^2_p = .516$), group ($F_{2,17} = 143.35$, $p < .001$, $\eta^2_p = .944$) and a hemisphere × group interaction ($F_{2,17} = 19.76$, $p < .001$, $\eta^2_p = .699$). As shown in Fig. 6B, among animals that were given SKF on sessions 1–3, but given Veh prior to tissue harvest (“Lesion – Veh (SKF Primed)”), there were no significant differences in M1 c-Fos compared to animals given exclusively Veh treatments. Relative to SKF primed animals treated with Veh, SKF primed animals given SKF on session 4 (“Lesion – Chronic

Fig. 5. Effect of L-DOPA on mRNA transcription of the genes associated with glutamate and GABA signaling in the primary motor cortex (M1; $n = 6–7$ per group). Rats received a unilateral lesion with 6-hydroxydopamine (or sham). After recovery, rats were treated for 14 d with Vehicle (Veh), except rats in the “Chronic” condition, which received daily L-DOPA (6 mg/kg). The next day, rats in the “Acute” and “Chronic” groups received L-DOPA (6 mg/kg), while others received Veh. All rats were decapitated 65 min later and M1 tissue was analyzed via real-time polymerase chain reaction. Hemispheres are denoted as either ipsilateral or contralateral (to lesion or sham). Percent change in mRNA was normalized to control (“Sham – Veh [contralateral]”). (A) NMDA subunit NR2A mRNA. (B) NMDA subunit NR2B mRNA. (C) Vesicular glutamate transporter type I (VGLUT1) mRNA. (D) Glutamic acid decarboxylase 67 kDa (GAD67) mRNA. * $p < .05$ vs. Lesion – Veh (ipsilateral); # $p < .05$ vs. own contralateral hemisphere.
SKF) showed increased c-Fos ipsilateral to lesion ($t_{12} = 9.46, p < .001$) and contralateral to lesion ($t_{12} = 20.08, p < .001$). However, a paired-samples t-test showed that chronic SKF increased c-Fos to a greater extent ipsilaterally than contralaterally ($t_{6} = 4.66, p = .003$). c-Fos expression was not significantly correlated with AIMs behavior (Fig. 7E, F).

ARC. Omnibus ANOVA examining ARC expression revealed an effect of group ($F_{2,17} = 21.58, p < .001$, $\eta^2_p = .717$), but no effect of hemisphere ($F_{1,17} = 0.28, p = .606$) or interaction ($F_{2,17} = 1.62, p = .226$). As with c-Fos, Veh-treated animals that were primed with SKF did not show increased ARC mRNA. Rats given chronic SKF showed increased ARC ipsilateral to lesion ($t_{12} = 3.79, p = .003$) and contralateral to lesion ($t_{12} = 2.75, p = .018$; Fig. 6C). Unlike c-Fos, ARC induction by SKF was bilaterally equivalent. ARC expression was not significantly correlated with AIMs behavior.

**DISCUSSION**

**Summary of findings**

For the first time, functional and structural changes in M1 were characterized using the popular unilateral 6-OHDA rat model of PD. Behavioral aspects of the model were validated by showing that rats manifested a PD motor impairment and developed dyskinesia upon exposure to l-DOPA or the D1 agonist SKF (Figs. 3A, B, 6A). 6-OHDA caused significant TH fiber loss in M1, but did so exclusively in the hemisphere ipsilateral to lesion (Fig. 2C–E). In lesioned animals, M1 tissue concentrations of DA and DOPAC were normal off-drug, but synthesis of DA from L-DOPA was reduced in M1 (Table 1). Among the genes examined in M1, expression was relatively normal after 6-OHDA lesion, but both l-DOPA and SKF caused abnormal bilateral activation of immediate-early genes (Figs. 4–6).

**Lesion-induced monoamine perturbations**

Using fiber-based stereology, we showed that chronic SKF increased c-Fos ipsilateral to lesion ($t_{12} = 9.46, p < .001$) and contralateral to lesion ($t_{12} = 20.08, p < .001$). However, a paired-samples t-test showed that chronic SKF increased c-Fos to a greater extent ipsilaterally than contralaterally ($t_{6} = 4.66, p = .003$). c-Fos expression was not significantly correlated with AIMs behavior (Fig. 7E, F).

**Lesion-induced monoamine perturbations**

Using fiber-based stereology, we showed that the density of TH-positive fibers in M1 was reduced by 6-OHDA lesion (down 75% compared to contralateral side; Fig. 2C–E). The same rats showed a 99% reduction in striatal TH (Fig. 2A, B), although the latter analysis had to be performed with densitometry, so the magnitude of the lesion may not be directly comparable.

Our data on TH fiber loss in M1 are the first to be performed with unbiased stereology (3-dimensional isotropy) and compare favorably with previous findings in PD animal models and patients. Using unilaterally 6-OHDA-lesioned rats, TH optical density in M1 was reduced by 93% when comparing the lesioned and
intact hemispheres (Halje et al., 2012). Gaspar et al. (1991) examined post-mortem tissue from PD patients and healthy controls, finding reductions in M1 TH density from 24% to 74%, depending on the cortical layer (analyzed with hemicycloid overlays, achieving 2-dimensional isotropy). From a technical perspective, TH staining appears to be the most exhaustive method of identifying DA fibers in the frontal cortex since TH antisera in the frontal cortex preferentially labels DA fibers; however, TH labeling is not entirely specific since a small percentage of stained axons are likely to be NE fibers (Hokfelt et al., 1977; Lewis et al., 1987; Miner et al., 2003).

The present study is the first to examine M1 monoamine concentrations in the rat 6-OHDA model of PD, one of the most widely used models of PD (Schober, 2004). In animals not exposed to L-DOPA, lesion with 6-OHDA did not affect DA or DOPAC tissue levels. Given that 6-OHDA lesion reduced M1 TH-positive fibers while DA concentrations remained normal, our data suggest that compensatory upregulation of DA synthesis occurred in remaining M1 DA fibers, as may be occurring in the DA-lesioned striatum (Song and Haber, 2000).

We also observed that lesion reduced M1 NE levels, regardless of whether the rat was given L-DOPA.

Fig. 7. Correlation between dyskinetic behavior and expression of the immediate-early gene c-Fos in the primary motor cortex (M1). Dyskinesia was scored with the abnormal involuntary movements (AIMs) scale while c-Fos mRNA was quantified via polymerase chain reaction. Analyses were performed only on rats that had a (unilateral) 6-hydroxydopamine lesion and received treatment with L-DOPA or the D₁ agonist SKF81297 (SKF). Data points reflect individual rat scores. The solid line is the least squares regression line while the dashed line signifies the 95% confidence interval for the slope of the regression line. (A, B) Acute L-DOPA: Previously drug-naïve rats were given their first dose of L-DOPA (6 mg/kg) and tissue was harvested 65 min later. (C, D) Chronic L-DOPA: Rats were treated daily for 15 d with L-DOPA 6 mg/kg and tissue was harvested 65 min after final injections. (E, F) Chronic SKF: Rats were treated four times with SKF 0.8 mg/kg over an 8 d period and tissue was harvested 120 min after final treatment. Note that the axes in panels E, F differ from the axes in panels A-D.
effects of L-DOPA on motor performance temporally
standing aspects of cortical dysfunction in PD and LID.

Our data suggest that more rigorous investigations
of locus coeruleus pathology may be important for under-
study, our data suggest that more rigorous investigations
of locus coeruleus pathology may be important for under-
standing aspects of cortical dysfunction in PD and LID.

**L-DOPA-induced monoamine perturbations**

When M1 tissue was examined 60 min after treatment, L-
DOPA increased M1 DA and DOPAC in all animals, but the
increase was attenuated in 6-OHDA-lesioned animals relative to sham-lesioned animals (Table 1). Reduced M1 synthesis of DA from L-DOPA is commensurate with human imaging studies showing reduced 18F-DOPA uptake in M1 of PD patients relative to controls (Moore et al., 2008). Because there are fewer TH-positive fibers in M1, there are fewer axons with the
capacity to synthesize DA from L-DOPA (this reaction requires the enzyme amino acid decarboxylase). Future studies should investigate if L-DOPA is increasing M1 extracellular DA release or simply increasing vesicular storage of DA, especially in sham animals, which have an intact DA system and did not exhibit LID behaviors.

We did not find any evidence to suggest that NE was
being synthesized from L-DOPA in M1, despite the
obvious biochemical feasibility of such events. Quite the
opposite, ANOVA of NE levels showed a main effect of
treatment with L-DOPA (cf. behavior in Figs. 3B, 6A, and
R N A i n

**L-DOPA-induced gene expression**

We also examined the effect of lesion and L-DOPA on the
transcription of genes involved in plasticity as well as
glutamate and GABA signaling within M1. This was
placed in the context of the behavioral phenotype of the
model. We showed that lesioned rats displayed forelimb
akinesia, a cardinal symptoms of PD, which was
partially reversible by L-DOPA (Fig. 3A). The beneficial
effects of L-DOPA on motor performance temporally
coincided with the expression of LID behaviors
(Fig. 3B). Likewise, the D1 agonist SKF caused
dyskinesia that was relatively equivalent to L-DOPA
(Fig. 6A).

First, we examined the immediate-early gene c-Fos, which has rapid effects on gene transcription and is implicated in pathological drug-induced learning (Perez-Cadahia et al., 2011). Lesion alone did not affect c-Fos transcription, but acute or chronic L-DOPA increased c-Fos to statistically equivalent levels (Fig. 4A). Previous studies have shown that L-DOPA induces c-Fos coincident with LID behavior, but these studies were performed in rats with multiple L-DOPA exposures so it has remained
as open question as to whether c-Fos is principally impor-
tant for the development or for the expression of LID
(Ostock et al., 2011; Halje et al., 2012). We found a large
correlation (r² = .820) between LID behavior and c-Fos
induction, but only for rats given acute L-DOPA and only in
M1 ipsilateral to lesion (Fig. 7A–D). If c-Fos was princip-
ally associated with the expression of LID, we would
expect c-Fos transcription to correlate with LID in rats
given chronic L-DOPA (which it did not) and also that
M1 c-Fos should be higher after chronic L-DOPA than
after acute L-DOPA (which it was not). Therefore, our
results suggest that M1 c-Fos predicts the development
of LID and may be involved in behavioral sensitization to L-DOPA.

Given the purported role of D1 receptor overactivation
during LID (Feyer et al., 2011), we also investigated M1
c-Fos after administration of a D1 agonist. Rats given
three doses of SKF and then left untreated for 2 d (SKF
Primed group) did not show c-Fos induction compared to
drug-naive animals (Fig. 6B). However, among rats
given SKF on all four sessions (Chronic SKF group),
c-Fos mRNA in M1 was increased 18-fold in the
hemisphere ipsilateral to lesion compared to Veh-treated
animals. The fact that c-Fos was not increased in animals
primed with SKF, but given Veh on test day demonstrates
that acute exposure to SKF—not SKF priming—is
responsible for inducing c-Fos. The magnitude of the
increase in c-Fos by D1 receptor stimulation appeared
to be greater than that evoked by chronic L-DOPA
(fourfold) despite a similar behavioral manifestation of
dyskinesia. However, it is important to note that c-Fos
was measured 65 min after L-DOPA, but 120 min after
SKF (cf. behavior in Figs. 3B, 6A and mRNA in
Figs. 4A, 6B) and that the onset of dyskinesia is slower with
L-DOPA than SKF since catabolism into DA is required for
psychoactivity of L-DOPA.

In addition to c-Fos, another immediate-early gene,
ARC, was examined since ARC has been implicated
in modulating synaptic activity and receptor trafficking
whereas c-Fos is more of a transcription modifier
(Bramham et al., 2008; Perez-Cadahia et al., 2011).
Similar to c-Fos, ARC expression was increased by both
L-DOPA and SKF (Figs. 4B, 6C). However, unlike c-Fos,
the increases in ARC were statistically equivalent bilater-
ally. This dissociation between c-Fos and ARC expres-
sion suggests that while L-DOPA promotes bilateral M1
plasticity in unilaterally lesioned rats, the changes occur-
ing are not entirely equivalent between hemispheres.
By extension, our data also provide further evidence that
the type of cortical plasticity measured by c-Fos vs. ARC
induction is at least partially independent. A recent study
in 6-OHDA-lesioned rats found that L-DOPA (3 mg/kg)
increased the number of M1 cells expressing ARC protein to a greater extent in rats that displayed LID vs. stable L-DOPA responders and preferentially increased ARC in the hemisphere ipsilateral vs. contralateral to lesion (Bastide et al., 2014). While the dose of L-DOPA, quantification method and dependent variable (mRNA vs. protein) differed between our respective studies, we note that in both experiments, there was mathematically more ARC in the ipsilateral vs. contralateral hemisphere.

Changes occurring in the hemisphere contralateral to lesion may be relevant for translational medicine, since PD patients manifest symptoms unilaterally during early disease-stages and contralateral hemisphere compensation may mask disease symptoms (Jankovic, 2008; Lieu and Subramanian, 2012). Indeed, there is evidence for bilateral changes in corticostriatal activity among unilaterally lesioned rats (Massie et al., 2010). The fact that L-DOPA and a D1 agonist increased c-Fos and ARC bilaterally in M1 while causing only unilateral dyskinesia suggests that some immediate-early gene activity in M1 may contribute to the pro-motor effects of DA replacement therapy.

There were few changes in the expression of genes involved in glutamate and GABA signaling (Fig. 5), which is surprising given widespread evidence for alterations in neuron firing patterns and receptor binding in the M1 glutamate and GABA system in PD and LID (Watts and Mandir, 1992; Ahmed et al., 2011; Brazhnik et al., 2012; Halje et al., 2012). Administration of acute L-DOPA to lesioned animals caused a small decrease in the expression of the NMDA NR2A subunit (Fig. 5A), a direction of effect that has been interpreted as signifying a reduction in long-term potentiation (Liu et al., 2004). PD patients typically show impaired M1 plasticity that is reversible by L-DOPA, but among patients with LID, long-term potentiation may remain deficient after L-DOPA is administered (Morgante et al., 2006; Doyon, 2008). The present data showing immediate-early gene induction by DA replacement are broadly suggestive of abnormal plasticity occurring in M1 (Figs. 4 and 6), but these changes appear to be largely independent of gene expression for glutamate and GABA markers (Fig. 5).

**CONCLUSIONS**

This is the first study to characterize changes in M1 monoamine innervation and gene expression using the 6-OHDA rat model of PD and drug-induced dyskinesia. Results show that 6-OHDA pathologically reduces catecholamine fibers, although compensatory plasticity may be sufficient to maintain relatively normal DA levels even if NE levels are coincidentally suppressed. Administration of L-DOPA or a D1 receptor agonist strongly induced two immediate-early genes in M1 involved in plasticity, suggesting that M1 is hyperactive during dyskinesia and providing pre-clinical support for the notion that stimulation that reduced M1 excitability may reduce LID (see Wagle-Shukla et al., 2007). In sum, M1 of the 6-OHDA rat model of PD demonstrates face validity with M1 of human PD patients, bolstering its utility for studying M1 dysfunction in PD and LID.

Exploring treatments that modulate M1 activity may elucidate novel therapeutic avenues for PD and LID.

**AUTHOR CONTRIBUTIONS**

Designed Research: DL, MMC, CYO, KBD, CB.
Performed Research: DL, MMC, CYO, KBD.
Analyzed Data: DL, MMC, CYO, KBD, CB.
Wrote Manuscript: DL, CB.
Provided Funding: KBD, CB.

Acknowledgements—The authors wish to thank Jessica A. George and Dr. Karen L. Eskow Jaunarajs for assistance with chromatography and animal testing. Thanks also to Dr. Terrence Deak, Dr. Lisa M. Savage and Dr. Caryl E. Sortwell for providing critical commentary on the manuscript.

This work was supported by National Institutes of Health grants R01-NS059600 (CB) and F31-NS066684 (KBD) as well as the Center for Development and Behavioral Neuroscience at Binghamton University. The authors declare that they have no competing financial interests.

**REFERENCES**

Korb E, Finkbeiner S (2011) Arc in synaptic plasticity: from gene to
Kleim JA, Lussnig E, Schwarz ER, Comery TA, Greenough WT
Jankovic J (2008) Parkinson’s disease: clinical features and
Hosp JA, Luft AR (2013) Dopaminergic meso-cortical projections to
Feyder M, Bonito-Oliva A, Fisone G (2011) L-DOPA-induced
dyskinesia and abnormal signaling in striatal medium spiny
neurons: focus on dopamine D1 receptor-mediated transmission. Front Behav Neurosci 5:71
Lewis DA, Hashimoto T, Volk DW (2005) Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6:312–324.


(Accepted 4 September 2015)
(Available online 9 September 2015)